Rationale, design and baseline characteristics of a 4-year (208-week) phase III trial of empagliflozin, an SGLT2 inhibitor, versus glimepiride as add-on to metformin in patients with type 2 diabetes mellitus with insufficient glycemic control
一项为期4年（208周）的III期临床试验旨在比较SGLT2抑制剂恩格列净与格列美脲作为二甲双胍联合用药治疗血糖控制不佳的2型糖尿病患者的疗效，本研究的理论依据、设计和基线特征如下：
期刊:Cardiovascular Diabetology
影响因子:10.6
doi:10.1186/1475-2840-12-129
Ridderstråle, Martin; Svaerd, Robbyna; Zeller, Cordula; Kim, Gabriel; Woerle, Hans J; Broedl, Uli C
